StockNews.com Begins Coverage on ObsEva (NASDAQ:OBSV)
by Sarita Garza · The Markets DailyEquities researchers at StockNews.com began coverage on shares of ObsEva (NASDAQ:OBSV – Get Free Report) in a report released on Thursday. The firm set a “hold” rating on the stock.
ObsEva Stock Performance
ObsEva has a twelve month low of $0.08 and a twelve month high of $2.14. The stock’s fifty day moving average is $0.01. The firm has a market cap of $7.94 million, a price-to-earnings ratio of -0.11 and a beta of 0.68.
About ObsEva
ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.
Featured Articles
- Five stocks we like better than ObsEva
- How to Invest in the Best Canadian Stocks
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- Investing in the High PE Growth Stocks
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Investing in Commodities: What Are They? How to Invest in Them
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?